Although the findings reported in Blood should be considered as hypothesis-generating and preliminary in nature, a small clinical trial suggested ibrutinib may protect against lung injury and improve pulmonary function in hypoxic patients with COVID-19.

The Journal of Internal Medicine stresses that, although the timing of antiviral therapy may significantly slow COVID-19 progression, the study was underpowered to evaluate the therapeutic effect of the drugs and they should continue to be used only in studies, not empirical use.

A JAMA “Original Investigation” seeks to discover the characteristics, clinical presentation, and outcomes of 5,700 patients hospitalized with COVID-19 in the United States, specifically in the New York City area.

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Beyond converting to telehealth platforms and limiting in-office visits, the Best Practices Committee of the NCCN shares essential approaches to help mitigate the transmission of COVID-19 among patients with cancer and the health care workers who treat them.

This study in Cancer suggests the possibility, pointing to qualitative results of clinical trial principal investigators, research staff, referring clinicians, and cancer center leaders regarding their attitudes and experiences with enrolling minority patients in cancer clinical trials.